Literature DB >> 23590680

Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats.

Xiu Luo1, Linlin Pan, Aifang Nie, Qidi Wang, Yanyun Gu, Fengying Li, Hongli Zhang, Wenyi Li, Xiaoying Li.   

Abstract

BACKGROUND: Glucagon-like peptide-1 (GLP-1) analogues have emerged as insulin secretagogues and are widely used in type 2 diabetic patients. GLP-1 analogues also demonstrate a promotion of beta cell proliferation and reduction of apoptosis in rodents. In the present study, we investigated the protection of pancreatic beta cells by early use (at the age of 2 weeks) of GLP-1 analogue, liraglutide in Gato-Kakizaki (GK) rats and explored the underlying mechanisms.
METHODS: The effects of liraglutide on glucose tolerance were evaluated by intraperitoneal glucose tolerance test (IPGTT) and insulin release tests (IRT). Ki67 and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) immunostaining, Western blots and real-time polymerase chain reaction were applied to evaluate cell proliferation, apoptosis and related gene expressions.
RESULTS: Our results demonstrated that early use of liraglutide improved glucose tolerance during liraglutide treatment in GK rats. Liraglutide increased pancreatic insulin contents and markedly reduced beta cell apoptosis. Liraglutide also downregulated pro-apoptotic gene expressions and reduced intra-islet macrophage infiltration.
CONCLUSIONS: This experiment reported for the first time that early use of liraglutide could protect beta cell failure in pre-diabetic GK rats through reduction of beta cell apoptosis and ameliorating islet inflammation.
© 2013 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Goto-Kakizaki rats; Goto-Kakizaki大鼠,利拉鲁肽,胰腺β细胞; liraglutide; pancreatic beta cells

Mesh:

Substances:

Year:  2013        PMID: 23590680     DOI: 10.1111/1753-0407.12061

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  6 in total

1.  Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2019-06-09       Impact factor: 19.112

2.  Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology.

Authors:  Qiuyue Guo; Yunsheng Xu; Jie Li; Wenrong An; Dan Luo; Chengcheng Huang; Yanqin Huang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-09-01       Impact factor: 3.168

3.  Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.

Authors:  Maarja Toots; Kadri Seppa; Toomas Jagomäe; Tuuliki Koppel; Maia Pallase; Indrek Heinla; Anton Terasmaa; Mario Plaas; Eero Vasar
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

4.  Intestinal electrical stimulation attenuates hyperglycemia and prevents loss of pancreatic β cells in type 2 diabetic Goto-Kakizaki rats.

Authors:  Xiaojun Ouyang; Shiying Li; Yan Tan; Lin Lin; Jieyun Yin; Jiande D Z Chen
Journal:  Nutr Diabetes       Date:  2019-02-06       Impact factor: 5.097

Review 5.  Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies.

Authors:  Safia Costes; Gyslaine Bertrand; Magalie A Ravier
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

6.  A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).

Authors:  Hiroshi Nomoto; Hideaki Miyoshi; Tomoo Furumoto; Koji Oba; Hiroyuki Tsutsui; Arina Miyoshi; Takuma Kondo; Kenichi Tsuchida; Tatsuya Atsumi; Naoki Manda; Yoshio Kurihara; Shin Aoki
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.